82 related articles for article (PubMed ID: 127462)
1. Correlation between the results of the migration inhibitory factor production test with DNA and the severity of the disease in the systemic lupus erythematosus patients.
Rovenský J; Svejcar J; Pekárek J; Zitnan D; Hajzok O; Cebecauer L
Z Immunitatsforsch Exp Klin Immunol; 1975 Aug; 150(1):24-30. PubMed ID: 127462
[TBL] [Abstract][Full Text] [Related]
2. Macrophage migration inhibitory factor in systemic lupus erythematosus.
Foote A; Briganti EM; Kipen Y; Santos L; Leech M; Morand EF
J Rheumatol; 2004 Feb; 31(2):268-73. PubMed ID: 14760795
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy.
Meehan RT; Dorsey JK
J Rheumatol; 1987 Apr; 14(2):252-8. PubMed ID: 3598995
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis.
Ayoub S; Hickey MJ; Morand EF
Nat Clin Pract Rheumatol; 2008 Feb; 4(2):98-105. PubMed ID: 18235539
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis.
Santos LL; Morand EF
Clin Chim Acta; 2009 Jan; 399(1-2):1-7. PubMed ID: 18838066
[TBL] [Abstract][Full Text] [Related]
6. The Crithidia luciliae kinetoplast immunofluorescence test in systemic lupus erythematosus.
Slater NG; Cameron JS; Lessof MH
Clin Exp Immunol; 1976 Sep; 25(3):480-6. PubMed ID: 786521
[TBL] [Abstract][Full Text] [Related]
7. [Plasma exchange therapy in children and adolescents with systemic lupus erythematosus (SLE)].
Pistor K; Neudorf U
Monatsschr Kinderheilkd; 1987 Jan; 135(1):47-50. PubMed ID: 3494196
[TBL] [Abstract][Full Text] [Related]
8. [Lupus erythematosus, modern aspects (author's transl)].
Canavese JC
Schweiz Rundsch Med Prax; 1977 May; 66(19):565-72. PubMed ID: 69300
[No Abstract] [Full Text] [Related]
9. Parameters of T cell mediated immunity to commensal micro-organisms in patients with chronic purulent rhinosinusitis: a comparison between delayed type hypersensitivity skin test, lymphocyte transformation test and macrophage migration inhibition factor assay.
van de Plassche-Boers EM; Drexhage HA; Kokjé-Kleingeld M; Leezenberg HA
Clin Exp Immunol; 1986 Dec; 66(3):516-24. PubMed ID: 3552334
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive therapy in systemic lupus erythematosus].
Deicher H
Monatsschr Kinderheilkd (1902); 1972 Jun; 120(6):215-7. PubMed ID: 4538326
[No Abstract] [Full Text] [Related]
11. Cellular immune reactivity to nuclear antigens in systemic lupus erythematosus.
Szabó G; Szegedi G; Hauch M; Gergely P; Fekete B; Petrányi G
Acta Med Acad Sci Hung; 1976; 33(1):41-50. PubMed ID: 1088242
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy in systemic lupus erythematosus.
Russell AS; Bretscher PA
J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():194-8. PubMed ID: 3302253
[TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive therapy of systemic lupus erythematosus].
Miescher PA; Lambert PH
Ther Umsch; 1971 Sep; 28(9):579-85. PubMed ID: 5122520
[No Abstract] [Full Text] [Related]
14. Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide.
Hrycek A; Kusmierz D; Dybała T; Swiatkowska L
Autoimmunity; 2007 Feb; 40(1):23-30. PubMed ID: 17364494
[TBL] [Abstract][Full Text] [Related]
15. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease.
Zou YQ; Lu LJ; Li SJ; Zeng T; Wang XD; Bao CD; Chen SL; Yang CD
Clin Biochem; 2008 May; 41(7-8):519-24. PubMed ID: 18261992
[TBL] [Abstract][Full Text] [Related]
16. [Leukocyte migration inhibition test in lupus erythematosus and dermatomyositis].
Sandhofer M; Fritz J
Z Hautkr; 1977 Sep; 52(17):906-12. PubMed ID: 910538
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
Petri M; Jones RJ; Brodsky RA
Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic drug treatment of lupus nephritis.
Donadio JV; Holley KE; Ilstrup DM
Am J Kidney Dis; 1982 Jul; 2(1 Suppl 1):178-81. PubMed ID: 7102666
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy.
Rood MJ; Borggreve SE; Huizinga TW
J Rheumatol; 2000 Aug; 27(8):2057-9. PubMed ID: 10955362
[No Abstract] [Full Text] [Related]
20. Clinical and immunological characterization of systemic lupus erythematosus in patients with circulating interferon and migration inhibitory factor.
Rovenský J; Bosák V; Zitnan D; Lackovic V; Borecký L; Pekárek J; Svejcar J; Lukác J; Matoková M
Int J Clin Pharmacol Res; 1984; 4(6):465-8. PubMed ID: 6085328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
